Nivolumab plus chemotherapy in Asian people with advanced or recurrent stomach or gastroesophageal junction cancer (ATTRACTION-4 study): a plain language summary - PubMed
4 hours ago
- #Clinical trial
- #Immunotherapy
- #Gastric cancer
- The ATTRACTION-4 study evaluated nivolumab plus chemotherapy in Asian patients with advanced or recurrent HER2-negative stomach or gastroesophageal junction cancer.
- Patients were randomly assigned to receive either nivolumab plus chemotherapy or placebo plus chemotherapy, with chemotherapy options being SOX or CAPOX.
- Nivolumab plus chemotherapy improved progression-free survival compared to placebo plus chemotherapy, though overall survival was similar in both groups (median ~17 months).
- Tumor response rates (shrinkage or disappearance) were higher in the nivolumab group, with longer duration of response.
- Side effects were similar between groups, with common ones being peripheral sensory neuropathy, decreased appetite, and nausea.
- Nivolumab plus chemotherapy did not add significant mental or physical health burdens beyond standard chemotherapy.
- The study supports nivolumab plus chemotherapy as a first-line treatment for advanced HER2-negative stomach cancer, now approved in over 50 countries.